Pre-made Vantictumab benchmark antibody ( Whole mAb, anti-FZD Family therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vantictumab biosimilar, Whole Mab: Anti-FZD Family therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vantictumab is a human IgG2 monoclonal antibody designed for the treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-611-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vantictumab biosimilar, Whole Mab: Anti-FZD Family therapeutic antibody
INN Name	Vantictumab
Target	FZD Family
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer;Non-small cell lung cancer;Pancreatic cancer
Development Tech	MorphoSys HuCAL Phage Display